Carbinoxamine extended-release - Tris Pharma

Drug Profile

Carbinoxamine extended-release - Tris Pharma

Alternative Names: Carbinoxamine maleate extended-release - Tris Pharma; Karbinal ER

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tris Pharma
  • Class Antiallergics; Antihistamines; Chlorobenzenes; Dimethylamines; Ethanolamines; Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Aug 2018 Cerecor acquires Carbinoxamine extended release from Avadel Pharmaceuticals before August 2018
  • 13 Feb 2018 Cerecor enters into purchase agreement with Avadel Pharmaceuticals to purchase and acquire all rights to rabeprazole
  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top